A functional assay to identify amyloidogenic light chains

References

• Mateos M-VSM, San Miguel JF. How should we treat newly diagnosed multiple myeloma patients? Hematology Am Soc Hematol Educ Program. 2013;2013:488–495.
   PubMedGoogle Scholar
• Rajkumar SV. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91:719–734.
   PubMed Web of Science ®Google Scholar
• Rios-Tamayo R, Sanchez MJ, Puerta JM, et al. Trends in survival of multiple myeloma: a thirty-year population-based study in a single institution. Cancer Epidemiol. 2015;39:693–699.
   PubMed Web of Science ®Google Scholar
• Comenzo RL. Plasma cell neoplasms, their precursor states, and their prediction of organ damage. JCO. 2014;32:2679–2682.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Katzmann JA, Kyle RA, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet. 2010;375:1721–1728.
   PubMed Web of Science ®Google Scholar
• Eisele L, Durig J, Huttmann A, et al. Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany. Ann Hematol. 2012;91:243–248.
   PubMed Web of Science ®Google Scholar
• Merlini G, Palladini G. Differential diagnosis of monoclonal gammopathy of undetermined significance. Hematology Am Soc Hematol Educ Program. 2012;2012:595–603.
   PubMedGoogle Scholar
• Rajkumar SV, Kyle RA, Plevak M, et al. Prevalence of light-chain monoclonal gammopathy of undetermined significance (LC-MGUS) among Olmsted County, Minnesota residents aged 50 years or greater. Blood. 2006;108:5060.
   Web of Science ®Google Scholar
• van Rhee F. Light-chain MGUS: implications for clinical practice. Lancet. 2010;375:1670–1671.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Gertz MA, Buadi F. What do I need to know about immunoglobulin light chain (AL) amyloidosis?. Blood Rev. 2012;26:137–154.
   PubMed Web of Science ®Google Scholar
• Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387:2641–2654.
   PubMed Web of Science ®Google Scholar
• Lin Y, Marin-Argany M, Dick CJ, et al. Mesenchymal stromal cells protect human cardiomyocytes from amyloid fibril damage. Cytotherapy. 2017;19:1426–1437.
   PubMedGoogle Scholar
• McWilliams-Koeppen HP, Foster JS, Hackenbrack N, et al. Light chain amyloid fibrils cause metabolic dysfunction in human cardiomyocytes. PLoS One. 2015;10:e0137716.
   PubMed Web of Science ®Google Scholar
• Blancas-Mejia LM, Ramirez-Alvarado M. Recruitment of light chains by homologous and heterologous fibrils shows distinctive kinetic and conformational specificity. Biochemistry. 2016;55:2967–2978.
   PubMed Web of Science ®Google Scholar
• Lakshman A, Abeykoon JP, Kumar SK, et al. Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. Am J Hematol. 2017;92:1146–1155.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Weiss BM, Plesner T, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016;128:37–44.
   PubMed Web of Science ®Google Scholar
• Badar T, Srour S, Bashir Q, et al. Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma. Eur J Haematol. 2017;98:263–268.
   PubMed Web of Science ®Google Scholar
• Dinner S, Witteles W, Witteles R, et al. The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis. Br J Haematol. 2013;161:367–372.
   PubMed Web of Science ®Google Scholar
• Sachchithanantham S, Offer M, Venner C, et al. Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis. Haematologica. 2015;100:1469–1476.
   PubMedGoogle Scholar
• Comenzo RL, Zhang Y, Martinez C, et al. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood. 2001;98:714–720.
   PubMed Web of Science ®Google Scholar
• Kourelis TV, Dasari S, Theis JD, et al. Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry. Blood. 2017;129:299–306.
   PubMed Web of Science ®Google Scholar
• Weiss BM, Hebreo J, Cordaro DV, et al. Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis. JCO. 2014;32:2699–2704.
   PubMed Web of Science ®Google Scholar
• Usnarska-Zubkiewicz L, Holojda J, Debski J, et al. Analysis of free serum light chains in patients suffering from multiple myeloma complicated by light-chain amyloidosis. Adv Clin Exp Med. 2014;23:531–538.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Landau H, Comenzo RL, et al. First-in-human Phase i/ii study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction. JCO. 2016;34:1097–1103.
   PubMed Web of Science ®Google Scholar
• Langer AL, Miao S, Mapara M, et al. Results of phase 1 study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis. Blood. 2015;126:188.
   Web of Science ®Google Scholar
• Richards DB, Cookson LM, Berges AC, et al. Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl J Med. 2015;373:1106–1114.
   PubMed Web of Science ®Google Scholar
• Mollee P, Renaut P, Gottlieb D, et al. How to diagnose amyloidosis. Intern Med J. 2014;44:7–17.
   PubMed Web of Science ®Google Scholar
• Palladini G, Basset M, Milani P, et al. Biomarker-based screening of organ dysfunction in patients with MGUS allows early diagnosis of AL amyloidosis. Blood. 2017;130(Suppl 1):1760.
   Web of Science ®Google Scholar
• Dorbala S, Vangala D, Semer J, et al. Imaging cardiac amyloidosis: a pilot study using (1)(8)F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging. 2014;41:1652–1662.
   PubMed Web of Science ®Google Scholar
• Hazenberg BP, van Rijswijk MH, Piers DA, et al. Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med. 2006;119:355.e15–355.e24.
   Web of Science ®Google Scholar
• Law WP, Wang WY, Moore PT, et al. Cardiac amyloid imaging with 18F-florbetaben PET: a pilot study. J Nucl Med. 2016;57:1733–1739.
   PubMed Web of Science ®Google Scholar
• Harper JD, Lansbury PT Jr. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem. 1997;66:385–407.
   PubMed Web of Science ®Google Scholar
• Wall J, Schell M, Murphy C, et al. Thermodynamic instability of human lambda 6 light chains: correlation with fibrillogenicity. Biochemistry. 1999;38:14101–14108.
   PubMed Web of Science ®Google Scholar
• Martin EB, Williams A, Wooliver C, et al. Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensity. PLoS One. 2017;12:e0174152.
   PubMed Web of Science ®Google Scholar
• Blancas-Mejia LM, Martin EB, Williams A, et al. Kinetic stability and sequence/structure studies of urine-derived Bence-Jones proteins from multiple myeloma and light chain amyloidosis patients. Biophys Chem. 2017;230:89–98.
   PubMed Web of Science ®Google Scholar
• Solomon A. Light chains of human immunoglobulins. Meth Enzymol. 1985;116:101–121.
   PubMed Web of Science ®Google Scholar
• Murphy C, Wang S, Williams T, et al. Characterization of systemic amyloid deposits by mass spectrometry. Meth Enzymol. 2006;412:48–62.
   PubMed Web of Science ®Google Scholar
• Lousada I, Comenzo RL, Landau H, et al. Light chain amyloidosis: patient experience survey from the amyloidosis research consortium. Adv Ther. 2015;32:920–928.
   PubMed Web of Science ®Google Scholar
• Fandrich M, Meinhardt J, Grigorieff N. Structural polymorphism of alzheimer abeta and other amyloid fibrils. Prion. 2009;3:89–93.
   PubMed Web of Science ®Google Scholar
• Finn TE, Nunez AC, Sunde M, et al. Serum albumin prevents protein aggregation and amyloid formation and retains chaperone-like activity in the presence of physiological ligands. J Biol Chem. 2012;287:21530–21540.
   PubMed Web of Science ®Google Scholar
• Milojevic J, Raditsis A, Melacini G. Human serum albumin inhibits abeta fibrillization through a “monomer-competitor” mechanism. Biophys J. 2009;97:2585–2594.
   PubMed Web of Science ®Google Scholar
• Zhou BR, Zhou Z, Hu QL, et al. Mixed macromolecular crowding inhibits amyloid formation of hen egg white lysozyme. Biochim Biophys Acta. 2008;1784:472–480.
   PubMedGoogle Scholar